Veradermics (NYSE:MANE) Issues Earnings Results

Veradermics (NYSE:MANE) released its quarterly earnings data on Tuesday. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.09, reports.

Veradermics Trading Up 1.2%

Shares of NYSE:MANE traded up $1.73 during trading on Wednesday, hitting $150.17. 170,821 shares of the company’s stock were exchanged, compared to its average volume of 638,826. The firm has a market cap of $6.27 billion and a P/E ratio of -79.11. The firm has a 50-day moving average price of $119.65 and a two-hundred day moving average price of $97.70. Veradermics has a 1-year low of $32.00 and a 1-year high of $152.82.

Key Stories Impacting Veradermics

These are some of the MANE stories that stood out recently:

• Positive Sentiment: Veradermics highlighted positive Part B results from Study 302 of VDPHL01, its treatment candidate for pattern hair loss. Coverage also pointed to 12-month hair-growth trial data, a potential catalyst for the late-stage biotech’s development prospects. Veradermics stock rises on 12-month hair growth trial data
• Positive Sentiment: Third-quarter EPS was a loss of $0.50, versus analysts’ expected loss of $0.59, a beat that may support investor sentiment. The company also reported recent corporate and clinical progress. Veradermics Q3 2026 results and progress
• Negative Sentiment: Despite the earnings beat, Veradermics remains loss-making: it reported a quarterly loss of $0.50 per share, and analysts expect a loss for the full fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Leerink Partners raised their price target on shares of Veradermics from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday. UBS Group set a $204.00 target price on shares of Veradermics in a research report on Thursday, October 22nd. Wall Street Zen upgraded Veradermics from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Citigroup upped their target price on shares of Veradermics from $160.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, B. Riley Financial increased their price objective on Veradermics from $170.00 to $204.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $174.57.

Insider Buying and Selling at Veradermics

In related news, Director Montanova Capital, Llc sold 750,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $107.25, for a total value of $80,437,500.00. Following the sale, the director directly owned 461,033 shares in the company, valued at $49,445,789.25. This trade represents a 61.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Timothy August Durso sold 43,500 shares of Veradermics stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $107.82, for a total value of $4,690,170.00. Following the transaction, the insider owned 78,142 shares in the company, valued at $8,425,270.44. This trade represents a 35.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 861,000 shares of company stock valued at $92,408,220.

Institutional Trading of Veradermics

A number of large investors have recently added to or reduced their stakes in the company. Montanova Capital LLC bought a new position in shares of Veradermics during the 2nd quarter worth approximately $512,533,000. Bamco Inc. NY increased its position in shares of Veradermics by 284.8% in the second quarter. Bamco Inc. NY now owns 229,581 shares of the company’s stock worth $28,225,000 after purchasing an additional 169,913 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Veradermics in the 2nd quarter valued at approximately $9,835,000. Wellington Management Group LLP bought a new stake in Veradermics during the second quarter worth $8,425,000. Finally, Alps Advisors Inc. lifted its position in shares of Veradermics by 31.2% during the 3rd quarter. Alps Advisors Inc. now owns 55,356 shares of the company’s stock worth $6,711,000 after buying an additional 13,150 shares during the last quarter.

Veradermics Company Profile

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.